Prescott Group Capital Management’s AbbVie ABBV Stock Holding History

Prescott Group Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$459K	Buy	+1,823	New	+$392K	0.04%	243

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Prescott Group Capital Management's ABBV Position: Q2 2026 in Review

Prescott Group Capital Management opened a new position in AbbVie (ABBV) in Q2 2026: 1,823 shares worth $459K. The stake represents 0.04% of the portfolio and ranks #243 among its holdings.

4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Prescott Group Capital Management held 1,823 shares of AbbVie worth $459K as of Q2 2026.
AbbVie was a new Prescott Group Capital Management position in Q2 2026.
AbbVie made up 0.04% of Prescott Group Capital Management's portfolio in Q2 2026, its #243 holding.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Prescott Group Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.